-
1
-
-
33746621996
-
Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision
-
Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 2006;103:11405-11410.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 11405-11410
-
-
Cursiefen, C.1
Chen, L.2
Saint-Geniez, M.3
-
2
-
-
33750430869
-
Corneal avascularity is due to soluble VEGF receptor-1
-
Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443:993-997.
-
(2006)
Nature
, vol.443
, pp. 993-997
-
-
Ambati, B.K.1
Nozaki, M.2
Singh, N.3
-
3
-
-
33750551972
-
Absence of blood and lymphatic vessels in the developing human cornea
-
Cursiefen C, Rummelt C, Junemann A, et al. Absence of blood and lymphatic vessels in the developing human cornea. Cornea 2006;25:722-726.
-
(2006)
Cornea
, vol.25
, pp. 722-726
-
-
Cursiefen, C.1
Rummelt, C.2
Junemann, A.3
-
4
-
-
33947651126
-
Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American ophthalmological society thesis)
-
Azar DT. Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American ophthalmological society thesis). Trans Am Opthalmol Soc 2006;104:264-302.
-
(2006)
Trans Am Opthalmol Soc
, vol.104
, pp. 264-302
-
-
Azar, D.T.1
-
5
-
-
33947513002
-
Proangiogenic role of ephrinB1/ EphB1 in basic fibroblast growth factor-induced corneal angiogenesis
-
Kojima T, Chang JH, Azar DT. Proangiogenic role of ephrinB1/ EphB1 in basic fibroblast growth factor-induced corneal angiogenesis. Am J Pathol 2007;170:764-773.
-
(2007)
Am J Pathol
, vol.170
, pp. 764-773
-
-
Kojima, T.1
Chang, J.H.2
Azar, D.T.3
-
6
-
-
35649027831
-
Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1
-
Seta F, Patil K, Bellner L, et al. Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1. Prostaglandins Other Lipid Mediat 2007;84:116-127.
-
(2007)
Prostaglandins Other Lipid Mediat
, vol.84
, pp. 116-127
-
-
Seta, F.1
Patil, K.2
Bellner, L.3
-
7
-
-
0031766152
-
Ocular neovascularization: An epidemiologic review
-
Lee P, Wang CC, Admis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43:245-269.
-
(1998)
Surv Ophthalmol
, vol.43
, pp. 245-269
-
-
Lee, P.1
Wang, C.C.2
Admis, A.P.3
-
10
-
-
34548815246
-
Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: Role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis
-
Nakao S, Hata M, Miura M, et al. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: Role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am J Pathol 2007;171:1058-1065.
-
(2007)
Am J Pathol
, vol.171
, pp. 1058-1065
-
-
Nakao, S.1
Hata, M.2
Miura, M.3
-
12
-
-
11144275177
-
Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris
-
Ciulla TA, Criswell MH, Snyder WJ, et al. Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris. Br J Ophthalmol 2005;89:113-119.
-
(2005)
Br J Ophthalmol
, vol.89
, pp. 113-119
-
-
Ciulla, T.A.1
Criswell, M.H.2
Snyder, W.J.3
-
13
-
-
0033976911
-
Photodynamic therapy for cornel neovascularization using topical administrated photosensitizer ATX-S10(Na) in experimental corneal neovascularization
-
Gohto Y, Obana A, Kanai M, et al. Photodynamic therapy for cornel neovascularization using topical administrated photosensitizer ATX-S10(Na) in experimental corneal neovascularization. Ophthalmic Surg Lasers 2000;31:55-60.
-
(2000)
Ophthalmic Surg Lasers
, vol.31
, pp. 55-60
-
-
Gohto, Y.1
Obana, A.2
Kanai, M.3
-
14
-
-
0038238254
-
Photodynamic therapy with Verteprofin in a rabbit model of corneal neovascularization
-
Holzer MP, Solomon KD, Vroman DT, et al. Photodynamic therapy with Verteprofin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci 2003;44:2954-2958.
-
(2003)
Invest Ophthalmol Vis Sci
, vol.44
, pp. 2954-2958
-
-
Holzer, M.P.1
Solomon, K.D.2
Vroman, D.T.3
-
15
-
-
60749092838
-
The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas
-
Oh JY, Kim MK, Shin MS, et al. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res 2009;34:85-91.
-
(2009)
Curr Eye Res
, vol.34
, pp. 85-91
-
-
Oh, J.Y.1
Kim, M.K.2
Shin, M.S.3
-
16
-
-
34247494559
-
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis
-
Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48:25-2552.
-
(2007)
Invest Ophthalmol Vis Sci
, vol.48
, pp. 25-2552
-
-
Bock, F.1
Onderka, J.2
Dietrich, T.3
-
17
-
-
38349081535
-
Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation
-
Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 2008;126:71-77.
-
(2008)
Arch Ophthalmol
, vol.126
, pp. 71-77
-
-
Bachmann, B.O.1
Bock, F.2
Wiegand, S.J.3
-
18
-
-
44649193281
-
Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation
-
Hos D, Bock F, Dietrich T, et al. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci 2008;49:1836-1842.
-
(2008)
Invest Ophthalmol Vis Sci
, vol.49
, pp. 1836-1842
-
-
Hos, D.1
Bock, F.2
Dietrich, T.3
-
19
-
-
33645028105
-
Contribution of VEGF and PEDF to choroidal angiogenesis: A need for balanced expressions
-
Tong JP, Yao YF. Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. Clin Biochem 2006;39:267-276.
-
(2006)
Clin Biochem
, vol.39
, pp. 267-276
-
-
Tong, J.P.1
Yao, Y.F.2
-
21
-
-
0026485002
-
Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis
-
Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992;359:843-845.
-
(1992)
Nature
, vol.359
, pp. 843-845
-
-
Shweiki, D.1
Itin, A.2
Soffer, D.3
-
22
-
-
0033856243
-
Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas
-
Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Investi Ophthalmol Vis Sci 2000;41:2514-2522.
-
(2000)
Investi Ophthalmol Vis Sci
, vol.41
, pp. 2514-2522
-
-
Philipp, W.1
Speicher, L.2
Humpel, C.3
-
23
-
-
0033941677
-
Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization
-
Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 2000;19:526-533.
-
(2000)
Cornea
, vol.19
, pp. 526-533
-
-
Cursiefen, C.1
Rummelt, C.2
Kuchle, M.3
-
24
-
-
0031965601
-
Requirement for vascular endothelial growth factor in wound- and inflammationrelated corneal neovascularization
-
Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammationrelated corneal neovascularization. Invest Ophthal Vis Sci 1998;39:18-22.
-
(1998)
Invest Ophthal Vis Sci
, vol.39
, pp. 18-22
-
-
Amano, S.1
Rohan, R.2
Kuroki, M.3
-
25
-
-
47949107165
-
Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis
-
Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 2008;27:743-745.
-
(2008)
Cornea
, vol.27
, pp. 743-745
-
-
Carrasco, M.A.1
-
26
-
-
64049105964
-
Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis
-
Chen WL, Lin CT, Lin NT. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 2009;50:1659-1665.
-
(2009)
Invest Ophthalmol Vis Sci
, vol.50
, pp. 1659-1665
-
-
Chen, W.L.1
Lin, C.T.2
Lin, N.T.3
-
27
-
-
38549140058
-
Subconjunctival bevacizumab injection for corneal neovascularization
-
Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008;27:142-147.
-
(2008)
Cornea
, vol.27
, pp. 142-147
-
-
Bahar, I.1
Kaiserman, I.2
McAllum, P.3
-
29
-
-
35348978227
-
Subconjunctival bevacizumab for vascularized rejected corneal grafts
-
Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg 2007;33:1991-1993.
-
(2007)
J Cataract Refract Surg
, vol.33
, pp. 1991-1993
-
-
Awadein, A.1
-
30
-
-
38549107051
-
Bevacizumab (Avastin) eye drops inhibit corneal neovascularization
-
Bock F, Konig Y, Kruse F, et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008;246:281-284.
-
(2008)
Graefes Arch Clin Exp Ophthalmol
, vol.246
, pp. 281-284
-
-
Bock, F.1
Konig, Y.2
Kruse, F.3
-
31
-
-
33748474191
-
Evolving European guidance on the medical management of neovascular age related macular degeneration
-
Chkravarthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006;90:1188-1196.
-
(2006)
Br J Ophthalmol
, vol.90
, pp. 1188-1196
-
-
Chkravarthy, U.1
Soubrane, G.2
Bandello, F.3
-
32
-
-
34247519047
-
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)
-
Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804-807.
-
(2007)
Br J Ophthalmol
, vol.91
, pp. 804-807
-
-
Manzano, R.P.1
Peyman, G.A.2
Khan, P.3
-
33
-
-
34548566924
-
The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea
-
Barros LF, Belfort R Jr. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 2007;79:389-394.
-
(2007)
An Acad Bras Cienc
, vol.79
, pp. 389-394
-
-
Barros, L.F.1
Belfort Jr., R.2
-
34
-
-
41149128844
-
Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs
-
Hurmeric V, Mumcuoglu T, Erdurman C, et al. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 2008;27:357-362.
-
(2008)
Cornea
, vol.27
, pp. 357-362
-
-
Hurmeric, V.1
Mumcuoglu, T.2
Erdurman, C.3
-
35
-
-
41149123475
-
Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin)
-
Kim TI, Kim SW, Kim S, et al. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008;27:349-352.
-
(2008)
Cornea
, vol.27
, pp. 349-352
-
-
Kim, T.I.1
Kim, S.W.2
Kim, S.3
-
36
-
-
39149083043
-
Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model
-
Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008;145:424-431.
-
(2008)
Am J Ophthalmol
, vol.145
, pp. 424-431
-
-
Papathanassiou, M.1
Theodossiadis, P.G.2
Liarakos, V.S.3
-
37
-
-
34247494559
-
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis
-
Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48:2545-2552
-
(2007)
Invest Ophthalmol Vis Sci
, vol.48
, pp. 2545-2552
-
-
Bock, F.1
Onderka, J.2
Dietrich, T.3
-
38
-
-
34548722080
-
Subconjunctival bevacizumab for corneal neovascularization
-
Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007;245:1577-1599.
-
(2007)
Graefes Arch Clin Exp Ophthalmol
, vol.245
, pp. 1577-1599
-
-
Erdurmus, M.1
Totan, Y.2
-
39
-
-
34250315760
-
Topical bevacizumab therapy for corneal neovascularization
-
DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007; 125:834-836.
-
(2007)
Arch Ophthalmol
, vol.125
, pp. 834-836
-
-
Destafeno, J.J.1
Kim, T.2
-
40
-
-
70349748824
-
Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy
-
Oh JY, Kim MK, Wee WR. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea 2009;28(9):1070-1073.
-
(2009)
Cornea
, vol.28
, Issue.9
, pp. 1070-1073
-
-
Oh, J.Y.1
Kim, M.K.2
Wee, W.R.3
-
41
-
-
65249103986
-
Topical bevacizumab in the treatment of corneal neovascularization: Results of a prospective, open-label, noncomparative study
-
Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: Results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009; 127:381-389.
-
(2009)
Arch Ophthalmol
, vol.127
, pp. 381-389
-
-
Dastjerdi, M.H.1
Al-Arfaj, K.M.2
Nallasamy, N.3
-
42
-
-
0021878871
-
Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea
-
Mohoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 1985;4:531-535.
-
(1985)
Curr Eye Res
, vol.4
, pp. 531-535
-
-
Mohoney, J.M.1
Waterbury, L.D.2
-
43
-
-
33744751811
-
The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization
-
Dell S, Peters S, Muther P, et al. The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. Invest Ophthalmol Vis Sci 2006;47:1928-1937.
-
(2006)
Invest Ophthalmol Vis Sci
, vol.47
, pp. 1928-1937
-
-
Dell, S.1
Peters, S.2
Muther, P.3
-
44
-
-
33745413422
-
Intracameral bevacizumab for iris rubeosis
-
Tuebingen Bevacizumab Study Group
-
Grisanti S, Biester S, Peters S, et al. Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158-160.
-
(2006)
Am J Ophthalmol
, vol.142
, pp. 158-160
-
-
Grisanti, S.1
Biester, S.2
Peters, S.3
-
45
-
-
66249099523
-
Simultaneous intravitreal and intracameral injection of bevacizumab (Avastin) in neovascular glaucoma
-
Yuzbasioglu E, Artunay O, Rasier R, et al. Simultaneous intravitreal and intracameral injection of bevacizumab (Avastin) in neovascular glaucoma. J Ocul Pharmacol Ther 2009;25:259-264.
-
(2009)
J Ocul Pharmacol Ther
, vol.25
, pp. 259-264
-
-
Yuzbasioglu, E.1
Artunay, O.2
Rasier, R.3
-
46
-
-
34548721616
-
Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients
-
Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-637.
-
(2007)
Am J Ophthalmol
, vol.144
, pp. 627-637
-
-
Brown, D.M.1
Regillo, C.D.2
-
47
-
-
38349122535
-
Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study
-
Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study. Am J Ophthalmol 2008;145:249-256.
-
(2008)
Am J Ophthalmol
, vol.145
, pp. 249-256
-
-
Bashshur, Z.F.1
Haddad, Z.A.2
Schakal, A.3
-
48
-
-
36248981014
-
Early bevacizumab treatment of central retinal vein occlusion
-
DOI 10.1016/j.ajo.2007.07.038, PII S0002939407006940
-
Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007;144:864-871. (Pubitemid 350122344)
-
(2007)
American Journal of Ophthalmology
, vol.144
, Issue.6
, pp. 864-871
-
-
Ferrara, D.C.1
Koizumi, H.2
Spaide, R.F.3
-
51
-
-
67449141559
-
Prevention and treatment of corneal neovascularization: Comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats
-
Hashemian MN, Moghimi S, Kiumehr S, et al. Prevention and treatment of corneal neovascularization: Comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res 2009;42:90-95.
-
(2009)
Ophthalmic Res
, vol.42
, pp. 90-95
-
-
Hashemian, M.N.1
Moghimi, S.2
Kiumehr, S.3
-
52
-
-
40649128599
-
Interaction between bevacizumab and murine VEGF-A: A reassessment
-
Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: A reassessment. Invest Ophthalmol Vis Sci 2008;49:522-527.
-
(2008)
Invest Ophthalmol Vis Sci
, vol.49
, pp. 522-527
-
-
Yu, L.1
Wu, X.2
Cheng, Z.3
-
53
-
-
33746541953
-
VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells
-
Zhao B, Ma A, Cai J, et al. VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells. Br J Ophthalmol 2006;90:1052-1059.
-
(2006)
Br J Ophthalmol
, vol.90
, pp. 1052-1059
-
-
Zhao, B.1
Ma, A.2
Cai, J.3
|